Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, aiming to expand into high‑throughput single‑cell sample prep and scale its presence in the rapidly growing single‑cell market. Qiagen framed the deal as a strategic fit to bridge its sample‑prep and informatics assets and accelerate offerings for pharma customers. Parse’s instrument‑free, scalable approach—already used in thousands of labs—gives Qiagen a plug‑and‑play entry into single‑cell workflows. The transaction accompanies management change at Qiagen and signals continued consolidation as larger life‑science suppliers buy specialist platforms to capture downstream sequencing and single‑cell demand.